Dasatinib/GIST

1,044 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,044
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
10
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Dasatinib/GIST

  1. 1. A Proposal for BMS-354825 (Dasatinib) in GIST Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
  2. 2. BMS-354825 (Dasatinib) Thiazolecarboxamide not structurally related to pyrido [2,3-d]-pyrimidine class of molecules Shah. Science 305: 399, 2004
  3. 3. • Mult-targeted oncogenic kinase inhibitor –Fyn, Yes, Src, Lck, Bcr-Abl, Epha-2, Kit, PDGFR, • > 100X potent than imatinib • Binds ABL in active and inactive conformation BMS-354825 (Dasatinib)
  4. 4. Ba/F3 BCR-ABL E255K M351T M244V G250E Q252H Q252R Y253F Y253H E255V F317L E355G F359V H396R F486S T315I 0 0.2 0.4 0.6 0.8 1 1.2 0 1 5 10 50 100 Relativegrowthafter48 hoursofdrugexposure Concentration of BMS-354825 (nM) Parental Ba/F3 cells “wt” BCR-ABL M351T E255K 0 1 5 10 50 100 “wt” BCR-ABL M351T T315I Shah Science. 305: 399 2004 BMS-354825 inhibits IR BCR-ABL mutants Ba/F3 cell lines in vitro
  5. 5. Dasatinib in imatinib-resistant CML Efficacy (%) CHR 87 CGR 59 Complete CGR 33 CHR 50 CGR 40 Complete CGR 30 CHR 28 CGR 56 Complete CGR 19 CP AP BP Talpaz et al., Sawyers et al., Kantarjian et al., ASCO 2005
  6. 6. Most Commonly Reported Non-Hematologic Toxicity Adverse event Grade 1–2 n (%) Grade 3–4 n (%) Elevated ALT 11 (28) 0 (0) Elevated creatinine 9 (23) 1 (3) Diarrhea 7 (18) 0 (0) Paresthesia 4 (10) 0 (0) Headache 4 (10) 0 (0) Nausea 2 (5) 0 (0) Peripheral edema 2 (5) 0 (0) Pleural effusion 1 (3) 1 (3) GI hemorrhage 0 (0) 2 (5) N=40 No QTc prolongation to >500 ms, with no cardiac symptoms
  7. 7. • Phase I study (N=19, 9 GIST) • Primary Endpoint –Dose/schedule: safe at 90 mg BID 5d/2d • Secondary Endpoint –PET imaging: 1 response –CT imaging: 5 SD 7-17 weeks BMS-354825 (Dasatinib) in GIST Evans et al, ASCO 2005
  8. 8. A Proposal for BMS-354825 (Dasatinib) in GIST Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
  9. 9. BMS-354825 (Dasatinib) in GIST: Inclusion Criteria • Histologically confirmed diagnosis of GIST • Refractory or relapsed disease after adequate imatinib. • Imatinib-intolerant • Generalized or limited progression
  10. 10. • Choi criteria will be used for response endpoints – Tumor size decrease of >10% or tumor density decrease of >15% • RECIST will be recorded for all patients BMS-354825 (Dasatinib) in GIST: Evaluations
  11. 11. • Two-arm phase IIa trial to simultaneously monitor safety and efficacy. • A 20% response rate with less than a 15% rate of toxicity is targeted. • Trial is terminated early if toxicity is high or efficacy is low. BMS-354825 (Dasatinib) in GIST: Design
  12. 12. • Safety and Efficacy • Progression-free survival and overall survival • Regression analyses to assess the ability of patient prognostic factors to predict time-to-event outcomes BMS-354825 (Dasatinib) in GIST: Analysis
  13. 13. A Proposal for BMS-354825 (Dasatinib) in GIST Jon Trent, MD, PhD Assistant Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
  14. 14. Choi Criteia Response Response Definition Complete Response (CR) -Disappearance of all disease -No new lesions Partial Response (PR) -A decrease in size of > or = 10% OR a decrease in CT density (HU) > or = 15% -No new lesions -No obvious progression of non-metastatic disease Stable Disease (SD) -Does not meet criteria for CR, PR, or PD -No symptomatic deterioration attributed to tumor progession Progression of Disease (PD) -An increase in unidimenstional tumor size of > or = 10% AND did not meet criteria for PR by CT density -Any new lesions, including new tumor nodules in a previous cystic tumor
  15. 15. • N=36 (31 resistant, 5 intolerant) • 15 to 180 mg/d for 5-7 d/wk • 27 pts with mutations • Responses: - Hematologic: 86% - Cytogenetic: 45% BMS-354825 (Dasatinib) in Imatinib- resistant CP-CML Sawyers CL, et al. Blood 104: 4a, 2004
  16. 16. Optional core biopsies Hx/PE, CT, Labs Days 1-28: BMS Restage after two cycles Registration BMS-354825 (Dasatinib) in GIST: Schema

×